Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Globe Newswire•14/10/2026•08:00 ET
0
Key Highlights
- ➤Tvardi management to present at Chardan’s 10th Annual Healthcare Conference October 20, 2026
- ➤Tvardi completed a Phase 1 healthy volunteer study of TTI-109
- ➤TTI-109 GI disease trials await IND clearance and additional funding
- ➤Tvardi is conducting a Phase 1b/2 TTI-101 trial in hepatocellular carcinoma
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10(th) Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.
Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference.
Get started
Create a free account to read the full story.